Article Text

Download PDFPDF
Future use of the Glasgow alcoholic hepatitis score
  1. I N Guha,
  2. W M Rosenberg
  1. University of Southampton, Liver Unit, Southampton, UK
  1. Correspondence to:
    Dr I N Guha
    Mail point 811, Level D, Southampton General Hospital, Trenoma Rd, Southampton S016 6YD, UK; guhaneil{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the findings of Forrest and colleagues (Gut 2005;54:1174–9) regarding their prognostic algorithm for alcoholic hepatitis, the Glasgow alcoholic hepatitis score (GAHS). The study uses robust clinical end points to develop an algorithm that has diagnostic advantages over the modified discriminant function score (DFS). We would like to discuss some of the future implications of this important study.

The overall death rate in the study was 23% at 28 days and the death rate of patients with a DFS >32 was 29% at 28 days in the derivation population. The latter figure is lower than the placebo arms of many of the randomised controlled trials of alcoholic hepatitis that range between 35% and 50%.1–3 This difference compared with the published literature may be attributable to …

View Full Text


  • IN Guha received grant support from Pfizer.

  • W M Rosenberg is a consultant for Schering-Plough, Roche, Gilead, Bayer, and Pfizer. He is the Chief Scientific Officer for HepCGen.

  • Conflict of interest: None declared.